Tumor Necrosis Factor Antagonist Use and Cancer in Patients With Rheumatoid Arthritis

Lymphoproliferative cancers include non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Hematologic cancers

More PDF Content

Tumor Necrosis Factor Antagonist Use and Cancer in Patients With Rheumatoid Arthritis
Demographic characteristics
Age, mean SD years
Female
White
Health service utilization
Charlson comorbidity score, mean SD
No. of physician visits, mean SD
No. of medicines taken, mean SD
Any hospitalization
RA severity–related covariates
RA-related surgery
Extraarticular manifestations
Difficulty walking 4.3 4.1 11.1 11.4 0.0 0.0 6.0 4.5
Pain in joints 32.5 27.0 28.2 25.4 8.5 10.5 25.7 20.0
CRP test ordered 16.9 8.9 22.1 12.9 21.1 8.5 19.8 9.8
ESR test ordered 37.7 39.4 48.3 49.4 55.5 54.2 45.6 48.1
RF test ordered 8.9 12.1 17.4 23.5 7.3 24.6 11.8 20.3
Arthocentesis 34.2 30.5 30.5 23.9 2.0 1.1 25.9 17.0
Injection (joint, tendon, etc.) 2.2 2.4 10.4 7.3 10.9 8.1 7.2 6.0
Corticosteroid treatment 41.1 23.9 51.7 46.2 69.6 52.4 51.3 41.5
Other cytotoxic DMARD treatment 12.8 2.2 18.1 2.7 47.4 1.9 22.2 2.2
Noncytotoxic DMARD treatment 18.4 20.0 20.1 18.1 36.4 31.5 22.9 24.1
Non-Hodgkin’s lymphoma 33,335.0 58 26.0 2.2 1.71–2.87
Multiple myeloma 33,410.0 19 9.3 2.0 1.26–3.12
Leukemia 33,423.7 22 16.6 1.3 0.85–1.97
Melanoma 33,377.7 29 12.8 2.3 1.55–3.22
Colorectal cancer 32,844.9 118 97.3 1.2 1.01–1.45
Lung cancer 31,532.8 169 95.6 1.8 1.52–2.05
Gastric cancer 33,414.1 12 14.2 0.8 0.46–1.44
Breast cancer 28,219.1 112 126.6 0.9 0.73–1.06
Prostate cancer 4,887.4 54 51.6 1.0 0.79–1.35
Uterine corpus/cervical cancer 28,432.0 16 30.9 0.5 0.31–0.82
Ovarian cancer 28,455.1 21 15.1 1.4 0.88–2.09
Urinary tract/bladder cancer 33,367.0 54 26.4 2.0 1.55–2.65
Renal cancer

Download Tumor Necrosis Factor Antagonist Use and Cancer in Patients With Rheumatoid Arthritis pdf from bibliomed.bib.uniud.it, 8 pages, 0.24KB.
Related Books

Leave a Reply